Dual inhibition of BET and HAT/p300 suppresses colorectal cancer via DR5- and p53/PUMA-mediated cell death.

Kuang, Chaoyuan; Tong, Jingshan; Ermine, Kaylee; Cai, Manbo; Dai, Fujun; Hao, Suisui; Giles, Francis; Huang, Yi; Yu, Jian; Zhang, Lin

Kuang, Chaoyuan; Tong, Jingshan; Ermine, Kaylee; Cai, Manbo; Dai, Fujun; Hao, Suisui; Giles, Francis; Huang, Yi; Yu, Jian; Zhang, Lin.

Afiliación

Kuang C; Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, United States.
Tong J; Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, United States.
Ermine K; Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, United States.
Cai M; Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA, United States.
Dai F; Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, United States.
Hao S; Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA, United States.
Giles F; Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, United States.
Huang Y; Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA, United States.
Yu J; Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, United States.
Zhang L; Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA, United States.

Front Oncol ; 12: 1018775, 2022.

Article en En | MEDLINE | ID: mdl-36313707

Palabras clave

BET inhibitor; apoptosis; colorectal cancer; drug development; epigenetics

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Front Oncol Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google